Updated results from a Phase 2a clinical trial suggest that namodenoson (CF102), an oral A3 adenosine receptor agonist, may provide lasting disease control for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have already received multiple rounds of treatment.
The study met its main safety goal, with no new safety concerns reported in patients receiving the drug as a second-, third-, or fourth-line treatment.
Among eight evaluable patients treated in the third-line setting who survived beyond two months, median overall survival exceeded five months, while progression-free survival extended beyond seven months. Three patients (37.5%) lived for more than seven months. In the second-line group, one of five patients remains alive more than 18 months after starting treatment.
The trial enrolled 20 patients who had progressed after previous therapies and received namodenoson 25 mg twice daily. Laboratory studies suggest the drug may improve the effectiveness of chemotherapy by blocking cancer-related signaling pathways and reducing drug resistance.
Based on these encouraging findings, the developer plans to launch a Phase 2b trial testing namodenoson in combination with chemotherapy for advanced pancreatic cancer.